News Articles and Montana BioScience Alliance Newsletters

MONTANA BIOSCIENCE ENTERPRISES IN THE NEWS

Last year, the World Trade Organization (WTO) proposed that biotechnology companies, including some in Montana, be required to give their formulas for COVID-19 vaccines to countries that aren’t as advanced as the U.S. in developing these technologies. The Biden administration has supported this proposal, but we have deep concerns about it.

The immuno-oncology market has grown at a compound rate of 10%, from $57 billion to $69 billion in 2021. It is expected to reach around $98 billion by 2025. This is a highly competitive market, so companies in this sector have to innovate rapidly by creating novel drugs and therapies. Montana’s Inimmune recently made the top-20 list.

A Montana State University undergraduate has been admitted to a prestigious European graduate program where she will advance her research in disease prevention and other applications of the growing field of bioinformatics.

Beginning with cannabis, the Missoula, MT based company is creating a self-contained and portable product that can detect impairment in real-time. The product will be sold to law enforcement agencies, and businesses with safety-critical employees.

Tonix Pharmaceuticals
|
March 9, 2022

Tonix Pharmaceuticals will collaborate with Massachusetts General Hospital to further develop a humanized monoclonal antibody, TNX-1500, to prevent organ transplant rejection, specifically in kidney transplants.

ARTICLES OF INTEREST

Researchers from Diaceutics and the Personalized Medicine Coalition has published a special report in JCO Precision Oncology  that provides an in-depth look at United States health systems’ efforts to deploy potentially paradigm-shifting targeted and immuno-oncology drugs to improve care for lung cancer patients.

Doctors have told health services to prepare for a new era of cancer screening after a study found a simple blood test could spot multiple cancer types in patients before they develop clear symptoms.

It’s been 60 years since President Kennedy delivered his iconic moonshot speech, marking a goal for America to launch a man into space to step foot on the moon, and bring him back to Earth. On Sept. 12, President Biden gave a speech at the Kennedy Presidential Library in Boston, outlining the progress on his own self-described moonshot: ending cancer.

The National Institute on Aging (NIA) offers early-stage funding opportunities to small businesses and researchers looking to commercialize innovative treatments or technologies to help people enjoy healthier lives as they age. The NIA Small Business Program is accepting applications for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) funding. Learn more about these open opportunities. The next deadline to apply is September 6, 2022. 

The federal Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs offer a lifeline to small medical technology companies that otherwise would not be able to secure the initial funding necessary for expensive research and development.

NEWSLETTER

Newsletter
|
November 30, 2022

View the Fall 2022 now!

Newsletter
|
August 25, 2022